Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
about
Potential impact of co-infections and co-morbidities prevalent in Africa on influenza severity and frequency: a systematic reviewEffectiveness of influenza vaccination for preventing influenza-related complications in people with asthma: a systematic review protocolThe Saudi Thoracic Society guidelines for influenza vaccinationsThe Pioneering Role of the Vaccine Safety Datalink Project (VSD) to Advance Collaborative Research and Distributed Data NetworksMonitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.A review of the changes to the licensing of influenza vaccines in Europe.Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.Update on antivirals and vaccines for seasonal and potential pandemic use.Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine.Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.Use of Fixed Effects Models to Analyze Self-Controlled Case Series Data in Vaccine Safety Studies.A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series designA pragmatic framework for single-site and multisite data quality assessment in electronic health record-based clinical researchTargeting influenza vaccinations of children.Transgenic sickle cell disease mice have high mortality and dysregulated immune responses after vaccinationPharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and childrenPrevention of influenza in healthy children.Sepsis, parenteral vaccination and skin disinfection.Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Vaccines and febrile seizures.Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.Signal detection of adverse events with imperfect confirmation rates in vaccine safety studies using self-controlled case series design.Preventing Infections in Sickle Cell Disease: The Unfinished Business.Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination.The "urban myth" of the association between neurological disorders and vaccinations.Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.The Influence of Vaccine on Febrile Seizure.Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients.Neurologic adverse events following influenza A (H1N1) vaccinations in children
P2860
Q23909568-640B9889-9363-437D-B10F-D9771388EA72Q28077038-86F25D0F-C3BB-4B38-AFB4-D599DC9762A3Q28394218-60AF22D8-E468-4DED-85BD-C74EDD24F2C1Q28602789-8E4AD8A3-0F92-4D64-A2A4-52E6CE6A8044Q30367585-BF4BCF4A-9BFE-43D7-8954-703168AF7805Q30379967-77A16A98-1592-4934-9960-B8A4551045D4Q30383245-5B59CBBE-E352-4D42-81FA-5C1109D913A5Q30389265-5EBE1D09-AB9A-47FF-94DE-F3F259CA5254Q30408522-61A7857C-74C3-4189-B76E-0AF0C3899E07Q30428839-10EE6882-D702-4759-AAE6-E73EF71E5A56Q30795124-268317B4-3810-4C4F-9904-317A21C44B05Q33405209-B8AFEE76-F97E-4F19-BAF1-A0CDA8A56008Q34301732-B8AA1716-3389-40E5-900B-9BA8A7F1EC51Q35223517-6CD36235-80FA-459F-AA35-62C002CAFC5DQ35805096-59AD5042-1A8C-4570-B2F9-4C218AB49EABQ36125536-717A30B2-F673-4C22-A1D5-7AB77C822A5EQ36256314-BAA974B1-B25B-4680-BF43-63A1CC964EA4Q37086288-9B1573EE-A793-4808-8B8B-0E56E558C462Q37147720-433A84A7-9D3B-4F72-9735-10F6EF2B7E8DQ37375883-CBAE137D-A9DC-48C9-AD40-5C13F9137A76Q37919183-1A5F712B-E0A3-4D10-9B70-4A1FF0166174Q38045920-C6397DDB-25FF-47B2-9F47-19BB5F3CBBE1Q38132266-FFEFAA70-41AC-40A9-B2BF-5BAC47C4AE55Q38137002-238D116A-B0C9-4ADA-B9B8-85017BD69C03Q38176828-B4472672-C4B9-4C54-B95E-E50AEB40B51FQ38721478-6BDB65EA-32F4-47A3-97A4-4939EB27650FQ40290470-A502A089-2DDF-4CEB-B52D-51255CBF7521Q43080823-E2CCEEDD-DC02-4310-B4C7-3DDDA68E88D8Q49739688-372F3F7B-E340-4707-9E16-F7D8EA7B2ED1Q52563841-CB42BEC1-41AC-4BAF-AE52-2C00436EEF1DQ55260871-BCCC3F4B-1C36-4943-B33F-B4D37C120A39Q57101873-E4606846-9511-4487-A8E6-1AE96E93AB6B
P2860
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@ast
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@en
type
label
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@ast
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@en
prefLabel
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@ast
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@en
P2093
P356
P1476
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
@en
P2093
David McClure
Edward Belongia
Edwin M Lewis
Eric K France
Frank DeStefano
Henry R Shinefield
James Nordin
Jason M Glanz
John P Mullooly
Kenneth M Zangwill
P304
P356
10.1001/JAMA.296.16.1990
P407
P577
2006-10-01T00:00:00Z